The recommended surveillance is based on current UKCGG guidelines, including an anticipated change in guidance, implemented in April 2025, recommending that all individuals with a GPV in BRCA1/BRCA2/PALB2 are eligible for enhanced breast cancer surveillance from the age of 25 years.15 The gene discussed is BRCA2; the disease is breast carcinoma.